Bevacizumab/steroids/thalidomideLack of efficacy and off label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1933卷 / 1期

关键词：

D O I：

10.1007/s40278-022-28071-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：120 / 120

相关论文

共 50 条

[31] Multiple drugsLack of efficacy and off label use: case report
Reactions Weekly, 2022, 1916 (1) : 296 - 296
[32] Multiple drugsLack of efficacy and off label use: case report
Reactions Weekly, 2021, 1860 (1) : 249 - 249
[33] RomidepsinLack of efficacy following off label use: case report
Reactions Weekly, 2022, 1922 (1) : 524 - 524
[34] CurcuminLack of efficacy following off label use: case report
Reactions Weekly, 2022, 1930 (1) : 212 - 212
[35] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[36] Multiple drugsLack of efficacy and off label use: case report
Reactions Weekly, 2021, 1845 (1) : 262 - 262
[37] Colchicine/mepolizumabLack of efficacy and off label use: case report
Reactions Weekly, 2023, 1957 (1) : 168 - 168
[38] Ketamine/naltrexoneLack of efficacy and off label use: case report
Reactions Weekly, 2023, 1948 (1) : 251 - 251
[39] Axitinib/sunitinibLack of efficacy and off label use: case report
Reactions Weekly, 2022, 1914 (1) : 101 - 101
[40] Chemotherapeutic DrugsLack of efficacy and off label use: case report
Reactions Weekly, 2021, 1843 (1) : 102 - 102

← 1 2 3 4 5 →